Platinum-based chemotherapy (chemo) with CS1001, an anti-PD-L1 antibody, for first-line advanced non-small cell lung cancer (NSCLC): Preliminary results from phase Ib cohorts of CS1001-101 study.
2020
e21687Background: Immuno-oncology (IO) monotherapy or combination with platinum-based chemo is the current standard of care for pts with PD-L1 expression ≥ 50% and EGFR, ALK, ROS1, BRAF negative ad...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI